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Positron Emission Tomography with 18Fluorodeoxyglucose
in Radiation Treatment Planning for Non-small Cell Lung
Cancer
A Systematic Review
Yee C. Ung, MD, FRCPC,* Andrea Bezjak, MDCM, FRCPC,† Nadia Coakley, MLIS,‡
and William K. Evans, MD, FRCPC,§ the Lung Cancer Disease Site Group of Cancer Care Ontario
Introduction: This article summarizes the available evidence on the
role of 18fluorodeoxy-D-glucose positron emission tomography
(PET) and PET-computed tomography in radiation treatment (RT)
planning for non-small cell lung cancer.
Methods: Relevant studies were identified through a systematic review
of the medical literature between January 1996 andMay 2010.Medline,
EMBASE, and the Cochrane databases were searched.
Results: Twenty-eight nonrandomized prospective and retrospec-
tive studies and one randomized trial reported in abstract form were
identified. There were no guidelines, systematic reviews, or meta-
analyses found in the search. There are no data available that
demonstrate an impact of PET-based RT planning on survival or
local recurrence rates. Nineteen studies reported changes in gross
tumor volume, and 11 studies reported changes in planning target
volume. The limited data suggest that PET in RT planning is more
likely to decrease the dose to the esophagus, but the data on the dose
to lung tissue are mixed. In two studies that evaluated the effect of
PET on total RT dose administered to patients, the RT dose in-
creased by approximately 15 Gy and tumor control probability
increased by 8.6% and 17.7% (p  0.026). In 12 studies, PET
detected distant metastases in 8 to 25% of patients and resulted in a
change from curative to palliative RT intent in 8 to 41% of patients.
Conclusions: The inclusion of PET imaging in the planning process
produces modifications in RT planning that may be beneficial. These
changes include a change in treatment intent from radical to pallia-
tive and substantial modifications of the gross tumor volume and
planning target volume. It is not certain that these changes result in
better clinical outcomes, but ongoing evaluation of PET for this
purpose is warranted.
Key Words: Positron emission tomography (PET), Systematic
review, Non-small cell lung cancer (NSCLC), Radiation treatment
planning.
(J Thorac Oncol. 2011;6: 86–97)
Lung cancer is the leading cause of cancer-related deaths inboth men and women in Canada.1 Radiation treatment
(RT) is indicated for use in approximately 60% of all patients
with lung cancer and is used for a variety of intents, including
curative, adjuvant, neoadjuvant, and palliative.2 RT is most
commonly applied in stage III non-small cell lung cancer
(NSCLC), where it is estimated that it might be indicated for
as many as 84% of patients.2
External beam radiotherapy (i.e., teletherapy) is the
most common form of RT and involves the targeting of
high-energy photons (i.e., x-rays) at cancerous tissues to
promote malignant cell death. Although healthy cells are
better able to repair damage from radiation, RT can kill
healthy tissues at sufficient dosage, and epithelial tissues are
particularly vulnerable. Tissue scarring can result from radi-
ation exposure and lead to reduced elasticity. This is espe-
cially relevant in lung cancer, where critical organs such as
the heart, spinal cord, esophagus, and the remainder of the
normal lung are often in the vicinity of tumor tissues (i.e.,
organs at risk [OARs]) and damage to these can be detrimen-
tal to the patient. Because of the possibility for significant
adverse effects from radiation, radiation oncologists are con-
tinually seeking methods to target RT more precisely. The
use of positron emission tomography (PET) with radiolabeled
[18F]-2-fluorodeoxy-D-glucose (18FDG) PET imaging infor-
mation is being evaluated as a possible means to improve
current RT practices.
RT dosage in lung cancer is generally provided to
patients in daily fractions, and a typical dose for a solid
epithelial tumor ranges from 60 to 70 Gy, with a fractionation
schedule for adults of 1.8 to 2.0 Gy per day. Radiation dosage
exposures are commonly described in terms of the percentage
of the organ receiving a particular total dose of radiation. For
example, V20 lung indicates the percentage of the lungs,
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excluding the planning target volume (PTV), that received a
dose of 20 Gy or more during the course of treatment. The
extent to which RT has achieved its objective in killing tumor
cells is conveyed by the concept of tumor control probability
(TCP). Imaging technologies, specifically planning computed
tomography (CT), are used in the RT planning process to
delineate tumors and adjacent healthy structures. Tradition-
ally, specialized CT scanners are combined with planning
software to virtually simulate the tumor and accurately place
x-ray beams. Newer approaches, such as three-dimensional
conformal radiotherapy or intensity-modulated RT are ex-
pected to further enhance these efforts.
RT planning requires precise definition of the region of
the diseased part of the body that is the target of the radiation
dose. In current practice, this region or “volume” is defined
three dimensionally in accordance with principles articulated
by the International Commission on Radiation Units and
Measurements. The gross tumor volume (GTV) and clinical
target volume (CTV) are clinical-anatomic concepts and refer
to the physical space occupied by disease. The GTV is “the
gross, palpable, visible or clinically demonstrable location
and extent of the malignant growth” and is generally defined
by all gross disease identified in scans (e.g., CT, PET, and
fused) and through other clinical information.3 The GTV
includes the primary tumor and metastatic lymphadenopathy.
The CTV contains the GTV and areas where there is a high
probability of subclinical malignant disease and typically
includes a volumetric extension of the GTV (e.g., a 0.6–0.8
cm margin and/or inclusion of draining lymph node re-
gions).4–6 Unlike GTV and CTV, the PTV is geometric
definition that is used directly in targeting a radiation beam.
The PTV contains the CTV and margins to account for
variability due to internal motion such as respiration in
patient setup (“setup margin”) or position of the target for
lung tumors (“internal margin”).7 Several algorithms have
been proposed to aid in the determination of the PTV, but
ultimately it is a clinical judgment that takes into account
adjacent topology, specifically the OARs for radiation
toxicity.
CT has traditionally been the primary source of ana-
tomic imaging information for target volume selection and
delineation in oncology. Nevertheless, CT is limited by the
fact that it has diminished resolution for normal soft tissue
structures and tumor extent. A number of studies have re-
ported significant variations in the delineations of GTV based
on CT data.8,9 There is reason to believe that the tumor
metabolic information provided by PET would be valuable in
RT planning. Tumor tissues generally exhibit more rapid
glycolysis than normal tissues, and the 18FDG tracer allows
for the metabolic imaging of this tissue. A number of studies
have compared the accuracy of PET in comparison with CT
for the purposes of diagnosis and staging in lung cancer.
PET has greater sensitivity and marginally greater spec-
ificity relative to CT in specific instances.10–14 This has
implications for RT planning in lung cancer. For instance, the
systematic review found PET to be superior to CT for
mediastinal staging in NSCLC.10 The greater sensitivity of
PET is believed to improve the detection of metastatic lymph
nodes that CT would have missed. PET may be better able to
detect distant metastases and allow for the exclusion of
patients from unnecessary radical RT. Conversely, PET may
result in the downstaging of CT-false-positive nodes and the
exclusion of nonmalignant tissues from the PTV. The benefit
of this for patients could be substantial: Graham et al.15 have
argued that a reduction of V20 lung by 5 to 17% would reduce
the incidence of grade 2 or greater pneumonitis occurring
within 24 months of treatment by up to 23%.
Despite this strong theoretical rationale for using PET
in RT planning, it is not yet clear that the addition of PET
imaging data has a clinically significant impact on planning.
Furthermore, assuming there is a benefit to including PET
data in planning, the optimal approach to using PET data is
not yet established. At present, PET tumor contouring re-
mains unsatisfactory, and there is little standardization in its
use. For instance, the delineation of tumor volumes based on
a metabolic activity threshold in PET has been shown to vary
both by tumor size and the background-to-tumor 18FDG
uptake ratio.16 Some clinicians include an area of lower
uptake, which some term as the “anatomic-biologic halo,” in
the GTV, and one study has shown that including this halo
improves coverage of the PTV,17 although, again, the practice
is not yet standard.
This systematic review was initiated because of the
increasing use and potential importance of PET in this area.
This systematic review will provide an evidence-based per-
spective as to whether planning based on PET and PET-CT
imaging data represents an improvement over planning based
on CT data alone and inform guidance on its role in RT
planning in the lung cancer setting.
PET is an imaging technique that gives high-resolution
images based on the use of biologically active compounds,
substrates, ligands, or drugs labeled with positron emitters.
These radiolabeled agents are processed in vivo in a manner
virtually identical to their nonradioactive counterpart, thereby
producing images and quantitative indexes of blood flow,
glucose metabolism, amino acid transport, protein metabo-
lism, oxygen consumption, and even cell division.
Traditional radiologic imaging (e.g., CT scan and mag-
netic resonance imaging) is based on structural information
and defines disease states based on gross anatomic changes,
whereas PET imaging is based on biochemical processes that
often precede any gross anatomic distortion. PET imaging is
now used primarily in oncological imaging due to the suc-
cessful application of 18F-FDG. This systematic review will
only evaluate the role of 18FDG-PET.
Imaging by PET is based on the detection of 511 keV
annihilation photons that are the result of positron, in this
case emitted from 18F, colliding with an electron. Photons
that are in coincidence are detected by two detectors at
180-degree angle from each other. These photons are consid-
ered to have originated from a point source along that axis.
All the collected information is then processed into the final
image in a two-dimensional or three-dimensional representa-
tion that reflects the concentration and distribution of the
radioisotope. This creates the image of FDG localization.
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The PET image does not provide accurate anatomic in-
formation aside from areas of normal physiological uptake (such
as the heart, kidneys, and bladder) and soft tissue uptake (e.g.,
muscle) that can provide an outline of the imaged body. There-
fore, advances in imaging technology have combined PET and
CT to provide both functional and anatomic information
simultaneously, thus improving its accuracy.
Various imaging instrumentation have been used in the
studies covered by this systematic review. The instrumenta-
tion varies from gamma camera coincidence imaging, to
dedicated PET scanner to PET-CT. It is not the intent of this
systematic review to evaluate the instrumentation, but differ-
ent instrumentation will have differing diagnostic perfor-
mance capabilities.18
METHODS
The evidence-based series guidelines developed by
Cancer Care Ontario’s Program in Evidence-Based Care
(PEBC) use the methods of the Practice Guidelines Devel-
opment Cycle.19 For this project, the core methodology used
to develop the evidentiary base was the systematic review.
Evidence was selected and reviewed by two members of the
PEBC Lung Disease Site Group and two methodologists.
This systematic review is a convenient and up-to-date
source of the best available evidence on PET in RT planning
for lung cancer. The PEBC is supported by the Ontario
Ministry of Health and Long-Term Care through Cancer Care
Ontario. All work produced by the PEBC is editorially
independent from its funding source.
Literature Search Strategy
The Medline (1996 to May 2010), EMBASE (1996 to
May 2010), and Cochrane Library (2007, Issue 1) databases
were searched for published practice guidelines, technology
assessments, systematic reviews, clinical trials, and studies.
Reference lists of articles and review articles were scanned
for additional citations. The Canadian Medical Association
Infobase (http://www.cma.ca/index.cfm/ci_id/54316/la_id/1.
htm), the National Guidelines Clearinghouse (http://www.
guideline.gov/), and other websites were searched for existing
evidence-based practice guidelines. The conference abstracts
of The American Society of Clinical Oncology, the American
Society for Therapeutic Radiology and Oncology, and the
European Society for Therapeutic Radiology and Oncology
(2002–2009) were searched for randomized studies. Search
terms indicative of lung cancer, RT planning, and PET
technology were used. The following MeSH terms were used:
lung, (cancer$ or carcinoma$ or neoplasm$) NSCLC, SCLC,
positron emission tomography, (PET or positron emission)
gamma camera, (tumo$ or target or treatment) (volume$ or
portal or plan$ or manage$) (GTV or PTV) (radiation$ or
radiotherapy$ or RT) plan$ (Appendix).
Study Selection Criteria
The most useful evidence regarding patient outcome.
Therefore, studies that reported on any relevant patient out-
come, such as survival, recurrence rates, treatment related
morbidity, and quality of life, were included.
Nevertheless, there was an a priori expectation that no
such data would be available. Therefore, studies that reported
data on more technical measures of RT planning were also
included, as these data would be useful in evaluating improve-
ments, if any, arising from the incorporation of PET-CT imag-
ing. These measures include changes in the target volume
definitions (e.g., GTV), radiation exposures to OARs, tumor dose
and TCP, intent of RT or in the management of patients, and rate of
geographical misses, and detection of distant metastases.
Articles were selected for consideration in this systematic
review of the evidence if they were published reports of studies
of any design that reported on aspects of RT planning for
patients with lung cancer that incorporated PET imaging data
and that compared the impact of consolidated PET-CT imaging
data with RT planning done in the absence of PET data.
Retrospective studies for which the RT planning was theoretical
(i.e., records were reviewed and investigators determined the RT
planning that would have occurred had a PET evaluation been
done) were included. Studies including patients with multiple
disease types (e.g., lung cancer and head and neck cancer) must
have reported data for patients with lung cancer specifically or
comprise a majority of patients with lung cancer to be eligible
for inclusion. Studies reporting data on the impact of PET on
clinical management of patients, including not only RT man-
agement but also surgical or chemotherapy management, were
included if data specific to RT management were reported.
Surveys of clinicians to measure the influence of PET
on RT planning were excluded as there is some subjectivity
involved in surveys, as were phantom studies. Studies re-
ported in a language other than English were excluded be-
cause of a lack of translation resources.
Synthesizing the Evidence
There was considerable inconsistency in the presen-
tation of data across included studies. The nature of the
studies and the data they provided did not lend themselves
to meta-analysis.
RESULTS
Literature Search Results
Abstracts for 219 studies were retrieved, and of
these, 28 journal publications were deemed appropriate for
inclusion in this report based on the eligibility criteria
outlined earlier. Five studies14,20–23 and two studies of
patients with small cell lung cancer (SCLC)24,25 that were
relevant to the research questions but did not report data
appropriate for summary in this report were excluded.
Table 1 outlines the quantity and type of studies identified to
answer the questions posed in this review. No practice guide-
lines, systematic reviews, or meta-analyses were identified, and
most studies consisted of small sample size observational pro-
spective or retrospective cohort studies. One randomized trial,
the The Impact of Positron Emission Tomography Imaging in
Stage Three Non-Small Cell Lung Cancer: A Prospective Ran-
domized Clinical Trial (PET-START) trial, has been reported in
abstract form.48
Table 2 presents several descriptive characteristics of
the included studies. The type of imaging technologies used
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in the studies varied: 10 studies evaluated hybrid PET-CT
scanners,17,26–31,49,52,53 four studies evaluated gamma camera
scanners,32–35 and the remainder evaluated dedicated PET scan-
ners. The combining (or coregistration) of PET and CT images
adds additional measurement error to the development of a
target volume definition. Coregistration has traditionally been
TABLE 1. Literature Search Results: Studies Included in the Evidence Summary Report
Question: What Role Should Positron Emission Tomography
(PET) Play in Radiation Treatment Planning for Lung
Cancer?
Prospective Cohort
(Applied RT Plan)
Retrospective
(Hypothetical RT Plan) References
Total included studies 19 4 17, 26–47
Does PET alter target volume definitions: GTV? (Table 3)
PTV? (Table 4)
10 4 17, 26–30, 32, 36, 38, 39, 40, 42–44
9 2 17, 29, 32, 33, 36, 37, 39, 41, 44–45
Does PET alter the radiation dose and exposure of the lungs or
esophagus? (Tables 5 and 6)
8 2 27, 31–34, 36–39, 44
Does PET alter the total radiation dose applied and/or the tumor
control probability? (Table 7)
1 1 31, 38
Does PET result in the detection of distant metastases and
change the intent of RT? (Table 8)
12 — 29, 32, 33, 35, 36, 40–44, 46, 47
RT, radiation treatment; GTV, gross tumor volume; PTV, planning target volume.
TABLE 2. Characteristics of Included Nonrandomized Studies
Study PET Scanner
PET/CT Image
Coregistration
Prospective or
Retrospective?
Sample
Size (n) Population
Ceresoli et al.43 GE Advance No Prospective 18 NSCLC
Gondi et al.26 Discovery LS (GE Medical) Hybrid PET/CT Prospective 14 NSCLC
Grills et al.27 — Hybrid PET/CT Prospective 21 NSCLC
Hong et al.30 Phillips Allegro Hybrid PET/CT Retrospective 19 NSCLC
MacManus et al.44 GE Quest 300-H No Prospective 10 NSCLC
Lewandowska et al.28 Biograph SL (Siemens) Hybrid PET/CT Retrospective 20 NSCLC
Ashamalla et al.17 GE-LSO-based Discovery ST Hybrid PET/CT Prospective 19 NSCLC
Brianzoni et al.29 Biograph Duo LSO (Siemens) Hybrid PET/CT Prospective 22 NSCLC and SCLCa
De Ruysscher et al.31 Biograph SOMATOM Sensation 16 (Siemens) Hybrid PET/CT Prospective 21 NSCLC
Deniaud-Alexandre et al.32 Picker Triple-Head Coincidence GC Software Prospective 101 NSCLCb
Messa et al.46 GE Advance Software Prospective 21 NSCLC
Roberts et al.41 PENN-PET 300-H No Prospective 17c NSCLC
van Der Wel et al.38 ECAT Exact 922 Visual Retrospective 21 NSCLC
Bradley et al.36 CTI ECAT HR (Siemens) Software Prospective 24 NSCLC
Schmücking et al.37 — Software Prospective 27 NSCLC
Erdi et al.45 GE Advance PET GC Visual  Software Prospective 11 NSCLC
Mah et al.33 Irix -PET3 (Marconi) GC Software Prospective 30 NSCLC
Giraud et al.34 Picker Dual Head CDET GC Software Prospective 12 NSCLC
Hicks et al.47 PENN-PET 300-H (UMG Medical Systems) No Prospective 153 NSCLC
Kalff et al.40 GE Quest 300-H No Prospective 59 NSCLCd
Mac Manus et al.42 GE Quest 300-H No Prospective 153 NSCLC
Roman et al.35 Picker Axis Dual-Head GC (Marconi) No Prospective 60 Lung cancer
Vanuytsel et al.39 CTI-Siemans 931/08/12 No Retrospective 105e NSCLC
Spratt et al.49 Discovery LS (GE Medical) Hybrid PET/CT Retrospective 11 NSCLC
Feng et al.50 — Software Prospective 14 NSCLC
Vinod et al.51 Gemini GXL-6 (Philips Medical) Software Retrospective 5 NSCLC
Hanna et al.52 Discovery LS (GE Medical) Hybrid PET/CT Prospective 28 NSCLC
Kruser et al.53 Discovery LS (GE Medical) Hybrid PET/CT Prospective 38 NSCLC  34 and
SCLC  4
a Approximately two thirds of patients had NSCLC.
b Of 101 patients, 22 had recurrent NSCLC.
c All patients had NSCLC, prior pneumonectomy, and were deemed at high risk for residual tumor recurrence.
d Primary and recurrent NSCLC.
e Seventy-three patients had positive lymph nodes; only these were included in volumetric analyses.
—, not reported; GC, gamma camera; PET, positron emission tomography; CT, computed tomography; NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer.
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a manual process involving the visual overlay of images with
the help of fixed markers, although more recently it has been
automated and improved through the use of computer soft-
ware and hybrid PET-CT devices. Studies using hybrid scan-
ners will have substantially less measurement error due to
coregistration.
Observational studies are inherently more susceptible
to bias than are randomized controlled trials. In most of the
studies included in this review, insufficient detail on efforts to
control bias in the treatment planning process was provided,
so it was assumed that planning was done by single or in
some cases multiple clinicians. The latter approach would
lead to interobserver variability in results.
A second bias relates to the sequential integration of
imaging data, a practice that may not reflect real-world
clinical practice. In all studies, RT plans were developed
using CT data alone and then subsequently with PET
imaging data included. Clinicians typically evaluate
PET-CT data simultaneously, and this may become stan-
dard practice as PET becomes more integrated in the RT
planning process. These potential biases could be con-
trolled for in studies by having independent evaluators
conduct planning on CT and PET-CT data separately. Only
three studies in this series used independent evaluators of
CT and PET-CT data.17,36,37
A third bias may be present in studies for which the
study design was a retrospective case review. The six retro-
spective studies in this series established a hypothetical PET-
based RT plan using PET data obtained for other purposes
(e.g., staging).28,30,38,39,49,51 These studies may be biased rel-
ative to prospective studies in that investigators may have
been less conservative in their planning definitions knowing
the definitions would not be applied in real patients. One
prospective study was also vulnerable to the same bias in that
a nontreating physician conducted the PET-based RT plan-
ning.36 Details on the clinicians involved in planning (e.g.,
whether they were treating physicians or not) were not
provided in most studies, and others might be subject to the
same threats to validity.
All studies evaluated patients with NSCLC (and in
three studies, patients with SCLC, and with “lung cancer”
without further specification were also included) for whom
radical RT was deemed appropriate on the basis of conven-
tional imaging data. Two studies reported including patients
with recurrent NSCLC,32,40 and one retrospectively reviewed
patients who were at high risk for tumor recurrence after
pneumonectomy.41 One study only included patients with
positive lymph nodes.39 Only limited details on specific
pathologic features were included in the remainder of the
studies in this series.
The studies included in this systematic review reported
data on a total of 1054 patients. Samples ranged in size from
5 to 153 patients, with a mean of 38 patients and a median of
59 patients. Most studies provided basic summary statistics
only (e.g., means, proportions, and ranges) and did not report
results from statistical testing (e.g., p values and confidence
intervals).
Measures and Outcomes
The PET START Trial
The PET START trial (NCT00136864) randomized
patients to either standard combined modality therapy for
stage III NSCLC or PET imaging before combined modality
therapy with curative intent. Data from this trial were re-
ported in abstract form at the 2009 American Society of
Clinical Oncology Annual Meeting.48 The primary outcome
was the proportion of patients who did not receive combined
modality therapy because their tumor was upstaged to stage
IV or their intrathoracic tumor was too extensive for radical
RT. The abstract provides insufficient detail to assess the
methodological quality and potential for bias in the trial with
respect to randomization method, blinding, and the balance of
prognostic factors between the arms. The trial was originally
designed to enroll 400 patients who had undergone conven-
tional staging for lung cancer and were found to have stage III
NSCLC. Nevertheless, it was reported that the trial was
stopped after a planned interim analysis in November 2008
because of superior efficacy on the PET arm. The trial was
stopped on the recommendation of the data and safety mon-
itoring board. In the abstract, data were available for 289
patients; 15% of patients in the PET-CT arm achieved the
primary outcome compared with 2.7% in the CT arm (p 
0.0002). No data were reported on other outcomes in the
abstract, but final analysis is pending.
The Impact of PET on Target Volume Definitions
As expected, no studies were identified that reported on
patient outcomes such as survival, recurrence, treatment-
related morbidity, or quality of life. Therefore, this review
will concentrate on the technical data reported by the in-
cluded studies.
The key technical measures (e.g., changes in GTV or
PTV) considered in this review were not reported consistently
across the studies; only one study reported on all the mea-
sures considered relevant in this review as outlined in the
study section criteria.36 For most measures, the data reported
were also inconsistent across studies: for example, some
reported the number of patients experiencing a change in
GTV and not the mean change in GTV. The following results
are comprehensive and have included any data reported in the
studies and, if possible, summary values calculated from raw
data provided in tables.
Changes in target volume definitions presented in this
section represent net changes: in some cases, it is likely that
PET data resulted in volume decreases due to a better differ-
entiation of benign masses and increases due to the identifi-
cation of involved mediastinal nodes missed by CT. One
study reported simultaneous GTV increases and decreases in
6 of 20 patients, although this study was an exception as most
reported only net changes.28
Gross Tumor Volume. Eighteen studies including a total of 587
patients reported changes inGTVas a result of the inclusion of PET
data in RT planning (Table 3).17,26–30,32,36,38,40,42–44,49,50,52,53 The
magnitude of GTV changes was reported in 11 of 18 of these
studies26,28,29,32,36,38,43,44,49,50,53; one other study reported the
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proportion of patients experiencing a change of more than
25%.17 In the nine studies26,28,29,32,36,43,49,50,53 that reported
the magnitude of the increase in GTV, the mean increase per
patient in patients with an increase ranged from 10.6 to 153%
(median study increase 49%); the greatest increase reported
for any single patient was 735%. In the 11 stud-
ies26,28,29,32,36,38,43,49,50,52,53 that reported the magnitude of the
GTV decrease in affected patients, the mean decrease per
patient across those studies ranged from 13.9 to 71% (median
study decrease 40.5%); the greatest decrease reported for a
single patient was 143%.
Planning Target Volume. Ten studies including a total of
262 patients reported changes in PTV as a result of the
inclusion of PET data in RT planning (Table
4).17,29,32,33,36,37,39,41,44,51 The magnitude of PTV changes was
reported in nine of these studies.17,29,32,33,36,37,39,44,45 In the
four studies29,32,35,36 that reported the magnitude of the PTV
increase, the mean increase per patient across those studies
ranged from 7 to 159% (median increase 27%); the greatest
increase for any single patient was reported as 381%. Three
other studies17,37,44 reported increases of PTV per patient of
10% or more in patients with an increase. In the six stud-
ies17,29,32,36,39,45 that reported the magnitude of PTV decrease,
the mean decrease per patient was less than 29% across all
studies; the greatest decrease for any single patient was 70%.
Three other studies33,37,44 reported decreases of PTV per
patient of 3% or more in affected patients.
Geographic Misses. Few studies provided specific details on
the inclusion of PET-positive tissue that had been missed in
CT-based planning; most reported aggregate data on GTV
expansions (reported earlier). Nevertheless, specific instances
of such geographic misses were reported in three studies.
Mah et al.33 reported that, in 5 of 23 patients suitable for
radical RT, FDG-avid nodes were detected within 5 cm of
the primary tumor; these nodes had not been included in
the CT-based GTV. Similarly, in a study by Lewandowska
et al.28 PET identified CT-occult mediastinal nodal metas-
tases in 9 of 20 cases, which were not included in the
CT-based GTV. In both of these studies, the GTVs were
expanded to incorporate these nodes. MacManus et al.
reported that in 3 of 10 cases, regions were located entirely
outside the CT PTV. These areas would not have been
TABLE 3. Patients Who Experienced Changes in Gross Tumor Volume (GTV) due to PET in
Radiotherapy Planning
Study n
Gross Tumor Volume (GTV)
Change ,
n (%)
Increase Œ Decrease 
nŒ (%) Range n (%) Range
Hanna et al.52 28 5 (18) — — — —
Spratt et al.49 11 8 (72) 3 (27%) — 4 (36%) —
Feng et al.50 14 14 (100) 4 (28) — 10 (71%) —
Kruser et al.53 38 25 (65) 17 (44%) — 19 (50%) —
Ceresoli et al.43 18 7 (39) 5 (114%) 40–235% 2 (61.5%) 39–84%
Gondi et al.26 14 14 (100) 2 (66%) 57–76% 12 (39%) 0.7–88%
Grills et al.27 21 17 (81) 12/20 (—) — 5/20 (—) —
Lewandowska et al.28 20 20 (100) 4 (32%) 10–80% 16 (45%) 3–82%
Hong et al.30 19 18 (94) — 18 (95%)a —
MacManus et al.44 10 4 (40) 0 (—) — 4 (—) —
Ashamalla et al.17 19 10b (53) 5 (—) — 5 (—) —
Brianzoni et al.29 22c 11 (50) 6 (10.6%) 1.7–26% 5 (13.9%) 2.2–26%
Deniaud-Alexandre et al.32 92d 45 (49) 24 (27%) 2–78% 21 (42%) 3–143%
van der Wel et al.38 21 12 (57) 0 (—) — 12 (28%)e —
Bradley et al.36 24 24 (100) 15 (153%) 5–735% 9 (22%) 1–78%
Kalff et al.40 41 12 (29) 5 (—) — 7 (—) —
Mac Manus et al.42 102f 38 (37) 22 (—) — 16 (—) —
Vanuytsel et al.39 73g 45 (62)h 16 (—) — 29 (—) —
Spratt et al.49 11 8 (72) 3 (27%) — 4 (36%) —
 is an upper case letter of delta from the Greek alphabet and is used to indicate change.
a Change in GTV was based on using the 40% maximum intensity threshold.
b Only changes 25% of GTV by CT reported.
c Approximately two thirds of patients had NSCLC.
d Of the 101 patients in this study, 92 were eligible for RT planning.
e Change in nodal volume only. No change in primary tumor volume.
f One hundred two of 153 patients received radical RT.
g Number of patients with positive lymph nodes (73/105).
h Change was insufficient or incorrect in nine patients, when compared with surgery information.
PET, positron emission tomography; RT, radiation treatment; CT, computed tomography; NSCLC, non-small cell lung cancer.
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contained within the target volume if the treatment was
delivered using the CT plan alone.44
The Impact of PET on Organs at Risk Radiation
Exposure and Dose
Esophageal Exposure and Dose. Five studies reported on
changes in esophageal radiation exposure due to PET in a
total of 166 patients (Table 5).27,31,32,34,38 The mean percent-
age of the esophageal volume exposed to a radiation dose of
50 to 55 Gy (V50eso and V55eso) per patient decreased in
three studies27,31,38 and increased in two studies32,34; the range
of changes in the studies was from10.4 to 4.5%. Two of the
three studies reporting a decrease in esophageal exposure
indicated that the mean decrease was statistically significant
with p values less than 0.005.31,38
Six studies including a total of 179 patients reported on the
impact of PET on the maximal esophageal radiation dose
(Table 6). The mean dose per patient received by the esoph-
agus decreased in four studies27,31,38,51 and increased in two
studies32,36; the range of changes in the studies was from
8.8 to 6.1 Gy. In one study, a decrease of 6.1 Gy was
reported to be statistically significant.38
TABLE 4. Changes in Planning Target Volumes due to PET in Radiotherapy Planning
Study n
Planning Target Volume (PTV)
Change ,
n (%)
Increase Œ Decrease 
nŒ (%) Range (%) n (%) Range (%)
MacManus et al.44 10 9 (90) 3 (—) 10 6 (—) 10%
Ashamalla et al.17 19 8 (42) 4 (—) 20 4 (20%) —
Brianzoni et al.29 25a 11 (44) 6 (5.4%) 1–22 5 (4.5%) 0.8–28
Deniaud-Alexandre et al.32 92b 43 (47) 23 (35%) 2–97 20 (27%) 7–67
Roberts et al.41 17 10 (58)c — (—) — — (—) —
Bradley et al.36 24d 24 (100) 15 (159%) 2–381 9 (9%) 2–49
Schmücking et al.37 27 27 (100) 2 (0.7%) — 25 (92%) 3–21
Erdi et al.45 11 11 (100) 7 (19%) 5–46 4 (18%) 2–48
Mah et al.33 30 — — (—) 30–76 — (—) 24–70
Vanuytsel et al.39 10e — — (—) — — (29%) —
 is an upper case letter of delta from the Greek alphabet and is used to indicate change.
a Approximately two thirds of patients had NSCLC. The data provided refer to CTV.
b Of the 101 patients in this study, 92 were eligible for RT planning.
c Change in target volume, dosage, or concurrent chemotherapy.
d Raw data provided in table.
e Data provided for only first 10/73 consecutive patients.
NSCLC, non-small cell lung cancer; CTV, clinical target volume; PET, positron emission tomography; RT, radiation treatment.
TABLE 5. Impact of PET on Lung and Esophageal Radiation Dose
Study N
V55eso,
a
Change 
V20 Lung
Change ,
N (%)
Increase Œ Decrease 
nŒ V20 Lung Range n V20 Lung Range
MacManus et al.44 10 — — — NS — — NS —
Grills et al.27 20 1%b — — 2% — — — —
De Ruysscher et al.31 21 10.4%, p  0.005 — — — — — 7.8%, p  0.001 —
Deniaud-Alexandre et al.32 92c 0.8%b 37/81 (46%) 15 154% 3–2000% 22 19% 3–100%
van Der Wel et al.38 21 8.7%, p  0.004 — — — — — 2.6%, p  0.012 —
Bradley et al.36 24 — 20 (83%) 15 7.3% 1–31% 5 6.2% 2–9%
Schmücking et al.37 27 — — — — — — — 5–17%
Mah et al.33 30 — — — NS — — NS —
Giraud et al.34 12 4.5% 5 (42%) 1 5.5% — 4 22.8% 7–49%
Vanuytsel et al.39 10d — 10 (100%) — — — 10 27%, p  0.001 8–59%
 is an upper case letter delta from the Greek alphabet and is used to indicate change.
a Percentage of the lung volume receiving 20 Gy (V20 lung).
b Voeso50.
c Of the 101 patients in this study, 92 were eligible for RT planning. For V20 lung, data were available only for 81 patients.
d Data provided for only first 10/73 consecutive patients.
NS, no statistically significant change observed; PET, positron emission tomography; RT, radiation treatment.
Ung et al. Journal of Thoracic Oncology • Volume 6, Number 1, January 2011
Copyright © 2010 by the International Association for the Study of Lung Cancer92
Lung Exposure and Dose. Ten studies including a total of
267 patients reported data on changes in lung radiation
exposure due to PET,27,31,32,33,34,36–39,44 and seven of these
provided data on the number of patients experiencing a
change or the mean value of the change (Table
5).27,29,31,32,34,36,38,39 The greatest reported increase in V20
lung for any single patient was 2000%; the greatest decrease
was 100%. Four of these studies32,34,36,39 reported a change in
V20 lung in between 46% and 100% of the studied patients.
Three studies31,38,39 reported a statistically significant de-
crease in V20 lung across the studied patients. Two studies33,44
reported that changes in V20 lung were not statistically sig-
nificant but did not provide data.
Four studies including a total of 154 patients reported on
the impact of PET on the maximal lung radiation dose (Table
6). The mean dose received by the lungs decreased in three
studies27,31,38 and increased in one study26; the range of
changes in the studies was from 5.1 to 1.6 Gy. One study
reported a statistically significant decrease in dose.36
Impact of PET on Total Radiation Dosage and
Tumor Control Probability
Modifications of the total radiation dose to the tumor
taking account of the need to limit the radiation dose to the
lung, esophagus, and spinal cord were reported to show an
increase in two studies by a mean of 13.7 Gy (from 55.2 
2.0 Gy to 68.9  3.3 Gy with PET, p  0.002) across 21
patients (including 15 stage III) and a mean of 15 Gy (from
56.0 5.4 Gy to 71.0  13.7 Gy, p 0.038) across 21 stage
III patients (Table 7). In both studies, patient-specific details
(e.g., the number of patients for whom the dose increased)
were not reported.
TCP increased in the two studies reporting on this
measure (Table 7). In one study, the TCP increased 17.7%
(from 6.3  1.5% to 24.0  5.6%, p  0.01) among 21
patients,31 and in the other, it increased 8.6% (from 14.2 
5.6% to 22.8 7.1%, p 0.026) among 21 patients.38 In this
latter study, the change was reported as being statistically
significant (p  0.026).
Impact of PET on Clinical Management and
Patient Outcomes
Changes in of RT Intent. Six studies reported that the inclu-
sion of PET imaging information in RT planning resulted in
the detection of distant metastases (Table 8).32,33,35,36,42,44 The
proportion of patients for which distant metastases were
identified ranged from 8 to 25% (median study identification
rate 17.5%) across these six studies.
Eleven studies reported on whether PET information re-
sulted in a change from curative to palliative RT in-
tent.29,32,33,35,36,40–43,46,47 The percent of patients for whom
the intent of RT was changed ranged from 8 to 41% of
patients across the 11 studies. Specific reasons for the change
in patient management were not consistently provided in
studies, although several cited more “extensive disease” or
distant metastases.
DISCUSSION
Proponents of PET believe that PET has value in the
clinical management of lung cancer by producing more ac-
curate diagnosis and staging, lower rates of futile thoracoto-
mies, and better clinical management decisions leading to
improved patient outcomes. This optimism for PET extends
to its role in RT planning for lung cancer. Many clinicians
believe that PET contributes to the identification of CT-occult
disease, particularly mediastinal lymph nodes, and leads to
the beneficial expansion of target volumes. Nevertheless, the
resolution of PET is not sensitive enough to detect micro-
scopic disease. The high sensitivity of PET has been demon-
strated to appropriately exclude patients from radical therapy
when distant metastases are present. There is growing con-
sensus that PET has a greater specificity to exclude nonma-
lignant areas, for example, in differentiating atelectasis, and
that this can appropriately reduce target volumes and radia-
tion exposure to patients. The intention of this review was to
systematically evaluate the available evidence related to these
TABLE 6. Impact of PET on Radiation Dosage (TCP)
Study n
 RT Dose (Gy)
Esophagus Lung
Vinod et al.51 1 2.5 —
Grills et al.27 20 1.5 1.2
De Ruysscher et al.31 21 8.8 5.1
Deniaud-Alexandre et al.32 92a 1.8 —
van Der Wel et al.38 21 6.1, p  0.004 1.1, p  0.004
Bradley et al.36 24 6.1 1.6
 is an upper case letter delta from the Greek alphabet and is used to indicate
change.
a Of the 101 patients in this study, 92 were eligible for RT planning.
RT, radiation treatment; PET, positron emission tomography; TCP, tumor control
probability.
TABLE 7. Impact of PET on Radiation Dosage and Tumor Control Probability (TCP)
Study n
Total RT Dose Tumor Control Probability
CT Based PET Based Change  CT Based PET Based  TCP (%)
De Ruysscher et al.31 21 55.2  2.0 68.9  3.3 13.7, p  0.002 6.3  1.5% 24.0  5.6% 17.7, p  0.01
van Der Wel et al.38 21 56.0  5.4 71.0  13.7 15, p  0.038 14.2  5.6% 22.8  7.1% 8.6, p  0.026
 is an upper case letter delta from the Greek alphabet and is used to indicate change. Values following the “” refer to the standard error of the mean.
PET, positron emission tomography; RT, radiation treatment; CT, computed tomography.
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and related issues and to determine what role, if any, PET
should play in RT planning for patients with lung cancer.
The PET-START trial48 is the only randomized trial
reported to date that addresses PET-CT for treatment plan-
ning in NSCLC. Unfortunately, this trial has only been
reported in abstract, with insufficient detail to fully assess its
quality and potential for bias. Nevertheless, once this trial has
been published in a peer-reviewed publication, it will likely
report significant data that may address at least some of the
issues described in detail later.
The review of the available literature showed that a
large proportion of patients experienced changes in target and
planning volumes through the use of PET imaging data (see
Tables 3 and 4 and accompanying text). Two studies reported
on the PET-based detection of geographic misses that re-
sulted in increases in target volumes. Although in some cases
the changes in volume are minor and would not be considered
clinically relevant, on the whole, they are substantial. In-
creases and decreases of greater than 10% in both GTV and
PTV were commonly reported across all studies. What is not
clear from these studies is whether the PET-based changes in
volumes were truly appropriate and led to better outcomes.
Very few studies have confirmed through surgical pathology
whether the changes in the RT field were appropriate, be-
cause biopsy correlation is often not possible in locally
advanced unresectable NSCLC. There is some reported data
on clinicopathological correlation.54–59 Nevertheless, assum-
ing that the majority of measured change was beneficial,
these values suggest that PET is contributing to both the
exclusion of nonmalignant tissue and the inclusion of CT-
occult tissue in RT planning.
Changes in volume size have the potential to produce
corresponding changes in organ radiation exposure if tissue is
included in or excluded from the PTV. The limited data
available suggest that the addition of PET to RT planning is
more likely to decrease the dose to the esophagus than to
increase it. Two of six studies27,31,32,34,38,51 reporting esoph-
ageal exposures (V50–55eso) reported statistically significant
decreases (10.4%, p  0.005, and 8.7%, p  0.004,
respectively).31,38 Changes in total radiation dosages to the
esophagus were variable across the studies, although one
study did report a statically significant (p  0.004) decrease
of 6.1 Gy.31,38
The available data regarding the effect of PET in RT
planning on dose to lung tissue are mixed. Although substan-
tial numbers of patients experience a change in V20 lung
(between 42% and 100% of patients across four stud-
ies),31,36,38,39 these changes involve both increases and de-
creases. Nevertheless, three studies31,38,39 did report statisti-
cally significant reductions in V20 lung. The data do suggest
that PET does reduce lung dose, with three of four stud-
ies31,36,38,39 reporting decreases (range of changes 5.1 to
1.5 Gy) and one of these reporting a statistically significant
decrease.38
Changes in the total administered radiation dosage and
TCP were reported in two studies only.31,38 In both studies,
the effect of PET was to increase the total radiation dosage
administered to patients (14, 15 Gy) and to increase the
TABLE 8. Impact of PET on the Detection of Distant Metastases and Treatment Intent
Study n
PET Detected Distant
Metastases n (%)
 Curative to
Palliative RT n (%) Reasons for Change
Ceresoli et al.43 21 3 (14) 3 (14) Bone metastases (n  2) large tumor not amenable to high-dose radiotherapy
(n  1)
MacManus et al.44 10 1 — Not reported
Brianzoni et al.29 25 — 3 (12) Not reported
Deniaud-Alexandre
et al.32
101 8 (8) 9 (9) Unexpected metastasis (n  8).a Extensive intrathoracic disease (n  1)
Messa et al.46 21 — 3 (14) Distant metastases or extensive intrathoracic disease (n  3)
Roberts et al.41 17 — 3 (18) Multiple metastases (n  1). Lung nodule and hilar adenopathy (n  1).
Regional recurrence and bone metastases (n  1)
Bradley et al.36 24 2 (8) 2 (8) Intrapulmonary metastases (n  1). Liver metastases (n  1)
Mah et al.33 30 7 (23) 7 (23)b Distant paratracheal node (n  1). Distant contralateral hilar nodes (n  1).
Distant contralateral node (n  1). Contralateral lower lobe lesion (n  1).
Left rib metastasis (n  1). Bilateral kidney metastases (n  1). Remote
diaphragmatic mass (n  1)
Hicks et al.47 153 — 34 (22) “More extensive disease” (n  34)
Kalff et al.40 59 — 17 (41)c “More extensive disease” (n  17)
Mac Manus et al.42 153 32 (21) 46d (30) Not reported
Roman et al.35 60 15e (25) 6 (10) Mediastinal disease (n  4) Distant metastases (n  2)
 is an upper case letter Delta from the Greek alphabet, and is used to indicate change.
a One of eight patients was false-PET-positive for intrapulmonary FDG uptake; some false-positive FDG-avid regions corresponded to concomitant pulmonary tuberculosis.
b This study also reported patients changed from palliative to curative intent because of PET identified less extensive disease (n  6) and patients for whom the modality of
treatment was changed (n  14).
c This study also reported patients changed from palliative to curative treatment (e.g., radical RT, brachytherapy, and surgery) intent (n  5).
d PET “strongly influenced” change in 10/46 and was “principal reason” in 36/46.
e Eight of 15 were true positive and 7/15 false positive (determined by CT): 5/7 were false-positive cerebral lesions.
PET, positron emission tomography; RT, radiation treatment; FDG, fluorodeoxy-D-glucose; CT, computed tomography.
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TCP of RT (18%, 9%); in both studies, the changes were
statistically significant (p  0.04, both studies). On the
assumption that PET allows for more accurate administration
of radiation to malignant structures, the reported net increases
in radiation dosage suggest that PET may contribute to more
effective RT.
There are data that suggest that the incorporation of
PET into RT planning has an impact on the management of
patients. In 12 studies,29,32,33,35,36,40–44,46,47 PET was reported
to detect distant metastases in 8 to 25% of patients and
change the intent of RT from curative to palliative in 8 to
41% of patients. The exclusion of patients with distant me-
tastases from undergoing futile radical radiation therapy pro-
vides the clearest benefit in patients with stage III NSCLC for
whom RT is indicated.60,61
There are no data available to date that show an impact
of PET-based RT planning on patient outcomes such as
survival or local recurrence rates. If PET is used in the
determination of disease extent, it is important to confirm that
areas of 18FDG uptake in mediastinal nodes or in distant,
particularly isolated, sites are confirmed histologically or
cytologically, so that patients are not inappropriately denied
potentially curative therapy.
This systematic review highlights the limitations of the
available evidence. There is rather poor consistency in re-
porting among the studies evaluating PET in RT planning.
The measures and outcomes described in studies vary con-
siderably, and the corresponding results are reported in in-
consistent manners. This heterogeneity in analysis and pre-
sentation is confusing to clinicians seeking guidance to use
this literature to inform treatment planning. In the individual
studies, there is rarely independent evaluation of the CT and
PET-CT imaging data to preclude bias. Investigators con-
ducting research in this area should evaluate the measures and
outcomes considered in this systematic review to facilitate
comparison of future studies. Such practices will allow for
the optimal use of research findings.
There are a number of issues regarding the use of PET
in RT planning for which there is little or no evidence to
inform clinical practice. Atelectasis is known to contribute to
interobserver variability in treatment planning in NSCLC.54
Nevertheless, it is not known whether PET contributes to or
diminishes the interobserver variability seen in the delinea-
tion of target volumes in this situation. The exclusion of
atelectatic tissue by PET is a reason to believe that PET may
reduce variability, but this supposition has not been widely
evaluated in empirical studies. Two studies incorporated
interobserver comparisons in their study designs: one found
that PET produced greater concordance between observers in
volumes17 and the other found that the effect of PET varied
by observer.33
The optimal PET intensity measure for defining the
tumor’s edge remains unclear. Some studies report using
regressive threshold functions,27 but the majority report using
a fixed threshold (percentage of the maximal standardized
uptake value intensity [e.g., 40–50%]) or do not report the
intensity measure used at all. Some argue that regressive or
lower fixed-threshold values (10–20%) are preferred.62,63 In
addition, some authors advocate contouring the distinct
“halo” seen around the area of maximal intensity of PET
because of the clinical ease of this approach and the lesser
interplanner variability it generates.17 There has been no
rigorous evaluation to determine an optimal threshold to date,
and there are technical aspects of PET that impede the use of
the technology. The evaluation of the lungs by PET is
affected by respiratory motion, which generates a degree of
measurement error thereby complicating coregistration. Hy-
brid PET/CT technologies help to reduce these errors but do
not remove them altogether. No studies in this series com-
pared hybrid PET/CT with dedicated PET devices.
Clearly, higher quality evidence is needed to guide
clinical and policy decision making regarding the use of PET
in RT planning. This evidence should be generated by well-
designed studies, which typically require large numbers of
patients and appropriate technological resources, including
high-quality PET scanners. A major study in patients with
lung cancer has recently been completed in Ontario48 and will
address at least some of the questions covered by this review.
CONCLUSIONS
Data from a number of small, nonrandomized studies
suggest that the inclusion of PET imaging in the planning
process produces modifications in RT planning that may be
beneficial. These changes include changing the intent of
treatment from curative to palliative in a substantial propor-
tion of patients and changes in target and planning volumes.
In many cases, these changes are substantial and clinically
significant, although it is not certain that these changes result
in better clinical outcomes. Data from these studies also
suggest that PET has a small but consistent protective effect
on the lungs and esophagus, and a few studies confirm a
benefit for PET in terms of increasing the total dose and TCP.
PET may be most useful in those cases where there is a large
area of lung opacification that may be due to tumor and/or
atelectasis/pneumonitis secondary to airway obstruction.
These data, taken as a whole, are highly suggestive of
a benefit of PET in RT planning in lung cancer, and further
evaluation of PET for this purpose is warranted. PET should
continue to be used cautiously as part of research protocols,
bearing in mind current uncertainties and evolving knowl-
edge. Clinicians should be particularly mindful of situations
in which PET is known to produce false-positive results (e.g.,
presence of inflamed lymph nodes due to pneumonitis).
When performing RT planning, clinicians should take into
consideration the technical specifications of the PET scanner
being used as these may modify the utility of the device for
RT planning purposes.
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7. Positron Emission Tomography/
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15. 13 or 14
16. (radiation$ or radiotherap$ or RT).ti,ab.
17. plan$.ti,ab.
18. 16 or 17
19. and/6,10,15,18
20. review.pt.
21. 19 not 20
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